Related references
Note: Only part of the references are listed.IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Naoyuki Nogami et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer
Jianghua Wu et al.
MODERN PATHOLOGY (2022)
Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Yolanda Lage Alfranca et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Efficacy of anti-PD-1 antibodies in NSCLC patients with anEGFRmutation and high PD-L1 expression
Ken Masuda et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer
Yoshinobu Saito et al.
CANCER SCIENCE (2021)
Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC
Yuki Takeyasu et al.
CLINICAL LUNG CANCER (2021)
Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis
Yangyun Huang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
Makoto Nishio et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2021)
Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
Meng Qiao et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy
Kartik Sehgal et al.
JAMA NETWORK OPEN (2021)
How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy
A. Fundytus et al.
ANNALS OF ONCOLOGY (2021)
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D. Rodriguez-Abreu et al.
ANNALS OF ONCOLOGY (2021)
An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
Jan Trost Jorgensen
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2021)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Meng Qiao et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Strategies to overcome resistance to immune checkpoint blockade in lung cancer
Ilaria Attili et al.
LUNG CANCER (2021)
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
M. Reck et al.
ESMO OPEN (2021)
Anti-PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status
Taichi Matsubara et al.
ONCOTARGETS AND THERAPY (2021)
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC
Jacek Jassem et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Michael J. Grant et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
Meichen Gu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis
Lei Sheng et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
Hayato Kawachi et al.
INVESTIGATIONAL NEW DRUGS (2020)
TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
G. R. Oxnard et al.
ANNALS OF ONCOLOGY (2020)
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
Mitsunori Morita et al.
BMC CANCER (2020)
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab
Francesco Pantano et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases
Rui Kitadai et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
A. J. Schoenfeld et al.
ANNALS OF ONCOLOGY (2020)
Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status
Yuichi Adachi et al.
CANCER MEDICINE (2020)
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Shirish Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B
Rintaro Norol et al.
THORACIC CANCER (2020)
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC
Lingzhi Hong et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert Jotte et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy
Satoshi Watanabe et al.
CANCER MEDICINE (2020)
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
Gary Middleton et al.
LANCET RESPIRATORY MEDICINE (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis
Yan Chen et al.
BMC CANCER (2020)
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data
Filippo G. Dall'Olio et al.
LUNG CANCER (2020)
A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis
Satoshi Ikeda et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer
Eugene Muchnik et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2019)
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
James Chih-Hsin Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
Arnaud Jeanson et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
K. Hastings et al.
ANNALS OF ONCOLOGY (2019)
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
Motohiro Tamiya et al.
INVESTIGATIONAL NEW DRUGS (2019)
Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial
Daichi Fujimoto et al.
LUNG CANCER (2019)
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
E. J. Aguilar et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer
Giulia Galli et al.
LUNG CANCER (2019)
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
Jong Yeob Kim et al.
CANCERS (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy et al.
ONCOIMMUNOLOGY (2019)
Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC
Li Jiang et al.
SCIENTIFIC REPORTS (2019)
Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
Qingyuan Huang et al.
ONCOIMMUNOLOGY (2018)
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
E. E. Vokes et al.
ANNALS OF ONCOLOGY (2018)
Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments
Shota Omori et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions
Ross A. Soo et al.
LUNG CANCER (2018)
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
Osamu Kanai et al.
THORACIC CANCER (2018)
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma A Systematic Review and Meta-analysis
Chee Khoon Lee et al.
JAMA ONCOLOGY (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer
Takayuki Shiroyama et al.
ANTICANCER RESEARCH (2018)
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Sabine Schmid et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Nasser Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis
Chee Khoon Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Paul C. Tumeh et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group
Herve Le Caer et al.
JOURNAL OF THORACIC DISEASE (2017)
Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives
Marc A. Emerson et al.
CANCER RESEARCH (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches
Pnina Brodt
CLINICAL CANCER RESEARCH (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A. Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prognostic effect of liver metastasis in lung cancer patients with distant metastasis
Yijiu Ren et al.
ONCOTARGET (2016)
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis
Mizuki Nishino et al.
JAMA ONCOLOGY (2016)
Interstitial lung abnormalities in treatment-naive advanced non-small-cell lung cancer patients are associated with shorter survival
Mizuki Nishino et al.
EUROPEAN JOURNAL OF RADIOLOGY (2015)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic Impact of Minimal Pleural Effusion in Non-Small-Cell Lung Cancer
Jeong-Seon Ryu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Metastatic sites and survival in lung cancer
M. Riihimaeki et al.
LUNG CANCER (2014)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review
Marije E. Hamaker et al.
LANCET ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer
Hirotsugu Kenmotsu et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials
Janette Vardy et al.
BMC CANCER (2009)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)